The US government has agreed to purchase another 105 million doses of Pfizer’s COVID-19 shots for $3.2 billion. They’re intended for a fall vaccination campaign, even though millions of COVID-19 doses have already been wasted, as demand plummets amidst news of their ineffectiveness.
STORY AT-A-GLANCE The U.S. Department of Health and Human Services announced that it, in partnership with the Department of Defense, agreed to purchase another 105 million doses of Pfizer’s COVID-19 shot — for $3.2 billion
The contract is intended to supply shots for a coming fall injection campaign and includes options to purchase up to 300 million doses
The decision came after a June 28 meeting of the U.S. Food and Drug Administration’s Vaccines and Related Biological Products Advisory Committee (VRBPAC), which recommended that an Omicron-specific component be included in COVID-19 booster shots in the U.S.
Pfizer stands to profit significantly from the contract and has forecast that its COVID-19 shot sales will reach $32 billion in 2022
VRBPAC voted 19-2 in favor of recommending booster shots that are Omicron-specific, even though panel members expressed uncertainty and guesswork surrounding the booster rollout In a news release quietly published June 29, 2022, the U.S. Department of Health and Human Services announced that it, in partnership with the Department of Defense, agreed to purchase another 105 million doses of Pfizer’s COVID-19 shot — for $3.2 billion.1…